Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Other Accumulated Expenses (2017 - 2025)

Crinetics Pharmaceuticals has reported Other Accumulated Expenses over the past 9 years, most recently at $1.8 million for Q2 2025.

  • Quarterly results put Other Accumulated Expenses at $1.8 million for Q2 2025, up 66.42% from a year ago — trailing twelve months through Jun 2025 was $1.8 million (up 66.42% YoY), and the annual figure for FY2024 was $901000.0, down 72.42%.
  • Other Accumulated Expenses for Q2 2025 was $1.8 million at Crinetics Pharmaceuticals, up from $1.7 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for CRNX hit a ceiling of $3.3 million in Q4 2023 and a floor of $323000.0 in Q4 2021.
  • Median Other Accumulated Expenses over the past 5 years was $906500.0 (2021), compared with a mean of $994777.8.
  • Biggest five-year swings in Other Accumulated Expenses: skyrocketed 875.22% in 2023 and later plummeted 72.42% in 2024.
  • Crinetics Pharmaceuticals' Other Accumulated Expenses stood at $323000.0 in 2021, then grew by 3.72% to $335000.0 in 2022, then skyrocketed by 875.22% to $3.3 million in 2023, then plummeted by 72.42% to $901000.0 in 2024, then surged by 99.67% to $1.8 million in 2025.
  • The last three reported values for Other Accumulated Expenses were $1.8 million (Q2 2025), $1.7 million (Q1 2025), and $901000.0 (Q4 2024) per Business Quant data.